{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:54:08Z","timestamp":1786737248346,"version":"build-2736575974"},"reference-count":158,"publisher":"e-Century Publishing Corporation","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/mfug2190","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T03:00:12Z","timestamp":1735614012000},"page":"5573-5597","source":"Crossref","is-referenced-by-count":2,"title":["Unraveling the complexity of follicular lymphoma: insights and innovations"],"prefix":"10.62347","volume":"14","author":[{"given":"Xijing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.cell.2020.06.039","article-title":"The lymphatic vasculature in the 21st century: novel functional roles in homeostasis and disease","volume":"182","author":"Oliver","year":"2020","unstructured":"Oliver G, Kipnis J, Randolph GJ and Harvey NL. The lymphatic vasculature in the 21st century: novel functional roles in homeostasis and disease. Cell 2020; 182: 270-296.","journal-title":"Cell"},{"key":"ref1","unstructured":"Nigam Y and Knight J. The lymphatic system 2: structure and function of the lymphoid organs. Nurs Times 2020; 116: 44-48."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Petrova TV and Koh GY. Biological functions of lymphatic vessels. Science 2020; 369: eaax4063.","DOI":"10.1126\/science.aax4063"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/s41467-022-28799-3","article-title":"Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma","volume":"13","author":"Liu","year":"2022","unstructured":"Liu X, Jin S, Hu S, Li R, Pan H, Liu Y, Lai P, Xu D, Sun J, Liu Z, Gao Y, Zhao Y, Liu F, Xiao Y, Li Y, Wen Y, Chen Z, Xu B, Lin Y, Ran M, Li Q, Yang S, Li H, Tu P, Haniffa M, Teichmann SA, Bai F and Wang Y. Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma. Nat Commun 2022; 13: 1158.","journal-title":"Nat Commun"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.4103\/jfmpc.jfmpc_1037_19","article-title":"Non-Hodgkin&#x2019;s lymphoma: a review","volume":"9","author":"Singh","year":"2020","unstructured":"Singh R, Shaik S, Negi BS, Rajguru JP, Patil PB, Parihar AS and Sharma U. Non-Hodgkin&#x2019;s lymphoma: a review. J Family Med Prim Care 2020; 9: 1834-1840.","journal-title":"J Family Med Prim Care"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/PPO.0000000000000451","article-title":"Lymphoma classification","volume":"26","author":"de Leval","year":"2020","unstructured":"de Leval L and Jaffe ES. Lymphoma classification. Cancer J 2020; 26: 176-185.","journal-title":"Cancer J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41375-020-0841-x","article-title":"Second malignant neoplasms after treatment of non-Hodgkin&#x2019;s lymphoma-a retrospective multinational study of 189 children and adolescents","volume":"35","author":"Attarbaschi","year":"2021","unstructured":"Attarbaschi A, Carraro E, Ronceray L, Andr&#xE9;s M, Barzilai-Birenboim S, Bomken S, Brugi&#xE8;res L, Burkhardt B, Ceppi F, Chiang AKS, Csoka M, Fedorova A, Jazbec J, Kabickova E, Loeffen J, Mellgren K, Miakova N, Moser O, Osumi T, Pourtsidis A, Rigaud C, Uyttebroeck A, Woessmann W and Pillon M; European Intergroup for Childhood Non-Hodgkin&#x2019;s Lymphoma (EICNHL) and the International Berlin-Frankfurt-M&#xFC;nster (i-BFM) Study Group. Second malignant neoplasms after treatment of non-Hodgkin&#x2019;s lymphoma-a retrospective multinational study of 189 children and adolescents. Leukemia 2021; 35: 534-549.","journal-title":"Leukemia"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A and Rawla P. Epidemiology of non-Hodgkin&#x2019;s lymphoma. Med Sci (Basel) 2021; 9: 5.","DOI":"10.3390\/medsci9010005"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","unstructured":"Carbone A, Roulland S, Gloghini A, Younes A, von Keudell G, L&#xF3;pez-Guillermo A and Fitzgibbon J. Follicular lymphoma. Nat Rev Dis Primers 2019; 5: 83.","journal-title":"Nat Rev Dis Primers"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","article-title":"Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025","volume":"63","author":"Kanas","year":"2022","unstructured":"Kanas G, Ge W, Quek RGW, Keeven K, Nersesyan K and Jon E Arnason. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025. Leuk Lymphoma 2022; 63: 54-63.","journal-title":"Leuk Lymphoma"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3390\/hemato3030032","article-title":"Evolution in the definition of follicular lymphoma and diffuse large B-cell lymphoma: a model for the future of personalized medicine","volume":"3","author":"Jaffe","year":"2022","unstructured":"Jaffe ES and Carbone A. Evolution in the definition of follicular lymphoma and diffuse large B-cell lymphoma: a model for the future of personalized medicine. Hemato 2022; 3: 466-474.","journal-title":"Hemato"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4132\/jptm.2021.09.29","article-title":"Follicular lymphoma: updates for pathologists","volume":"56","author":"Khanlari","year":"2022","unstructured":"Khanlari M and Chapman JR. Follicular lymphoma: updates for pathologists. J Pathol Transl Med 2022; 56: 1-15.","journal-title":"J Pathol Transl Med"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Zhou T, Pittaluga S and Jaffe ES. Molecular insights into the pathogenesis of follicular lymphoma. Ann Lymphoma 2021; 5.","DOI":"10.21037\/aol-20-49"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.3748\/wjg.v29.i12.1852","article-title":"Review of lymphoma in the duodenum: an update of diagnosis and management","volume":"29","author":"Iwamuro","year":"2023","unstructured":"Iwamuro M, Tanaka T and Okada H. Review of lymphoma in the duodenum: an update of diagnosis and management. World J Gastroenterol 2023; 29: 1852-1862.","journal-title":"World J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1016\/j.ajpath.2023.08.012","article-title":"Evolution of lymphoma diagnosis in the era of personalized medicine: a marriage of pathology and genomics for clinical practice","volume":"193","author":"Jaffe","year":"2023","unstructured":"Jaffe ES. Evolution of lymphoma diagnosis in the era of personalized medicine: a marriage of pathology and genomics for clinical practice. Am J Pathol 2023; 193: 1880-1886.","journal-title":"Am J Pathol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ijscr.2020.06.029","article-title":"Diffuse large B-cell and follicular lymphoma presenting as a slowly growing compressive goiter: a case report and literature review","volume":"72","author":"Lin","year":"2020","unstructured":"Lin N, Vargas-Pinto S, Gisriel S, Xu M and Gibson CE. Diffuse large B-cell and follicular lymphoma presenting as a slowly growing compressive goiter: a case report and literature review. Int J Surg Case Rep 2020; 72: 615-619.","journal-title":"Int J Surg Case Rep"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ajh.25696","article-title":"Follicular lymphoma: 2020 update on diagnosis and management","volume":"95","author":"Freedman","year":"2020","unstructured":"Freedman A and Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 2020; 95: 316-327.","journal-title":"Am J Hematol"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Matasar MJ, Luminari S, Barr PM, Barta SK, Danilov AV, Hill BT, Phillips TJ, Jerkeman M, Magagnoli M, Nastoupil LJ, Persky DO and Okosun J. Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs. Oncologist 2019; 24: e1236-e1250.","DOI":"10.1634\/theoncologist.2019-0138"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Piris MA, Medeiros LJ and Chang KC. Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis. Pathology 2020; 52: 154-165.","DOI":"10.1016\/j.pathol.2019.09.005"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/ajh.26737","article-title":"Follicular lymphoma: 2023 update on diagnosis and management","volume":"97","author":"Jacobsen","year":"2022","unstructured":"Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol 2022; 97: 1638-1651.","journal-title":"Am J Hematol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3324\/haematol.2021.278717","article-title":"Prospects in the management of patients with follicular lymphoma beyond first-line therapy","volume":"107","author":"Qualls","year":"2022","unstructured":"Qualls D and Salles G. Prospects in the management of patients with follicular lymphoma beyond first-line therapy. Haematologica 2022; 107: 19-34.","journal-title":"Haematologica"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/cei.13620","article-title":"Lymphadenopathy at the crossroad between immunodeficiency and autoinflammation: an intriguing challenge","volume":"205","author":"Costagliola","year":"2021","unstructured":"Costagliola G and Consolini R. Lymphadenopathy at the crossroad between immunodeficiency and autoinflammation: an intriguing challenge. Clin Exp Immunol 2021; 205: 288-305.","journal-title":"Clin Exp Immunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1038\/s41598-023-32736-9","article-title":"Long-term outcomes of patients with primary intestinal follicular lymphoma managed with watch-and-wait strategy","volume":"13","author":"Iwamuro","year":"2023","unstructured":"Iwamuro M, Tanaka T, Ennishi D, Matsueda K, Yoshioka M, Miyahara K, Sakaguchi C, Nishimura M, Nagahara T, Mannami T, Takenaka R, Oka S, Inoue M, Takimoto H, Inaba T, Kobayashi S, Toyokawa T, Tsugeno H, Suzuki S, Sawada S, Tanaka S, Tsuzuki T and Okada H. Long-term outcomes of patients with primary intestinal follicular lymphoma managed with watch-and-wait strategy. Sci Rep 2023; 13: 5858.","journal-title":"Sci Rep"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3389\/fonc.2020.00651","article-title":"Primary cutaneous B-cell lymphomas: an update","volume":"10","author":"Vitiello","year":"2020","unstructured":"Vitiello P, Sica A, Ronchi A, Caccavale S, Franco R and Argenziano G. Primary cutaneous B-cell lymphomas: an update. Front Oncol 2020; 10: 651.","journal-title":"Front Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.3390\/cancers14204972","article-title":"Genetics abnormalities with clinical impact in primary cutaneous lymphomas","volume":"14","author":"Gallardo","year":"2022","unstructured":"Gallardo F and Pujol RM. Genetics abnormalities with clinical impact in primary cutaneous lymphomas. Cancers (Basel) 2022; 14: 4972.","journal-title":"Cancers (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1111\/jdv.17219","article-title":"Dermoscopic and trichoscopic features of primary cutaneous lymphomas - systematic review","volume":"35","author":"S&#x142","year":"2021","unstructured":"S&#x142;awi&#x144;ska M, Soko&#x142;owska-Wojdy&#x142;o M, Olszewska B, Nowicki RJ, Sobjanek M and Zalaudek I. Dermoscopic and trichoscopic features of primary cutaneous lymphomas - systematic review. J Eur Acad Dermatol Venereol 2021; 35: 1470-1484.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"6772","DOI":"10.1038\/s41467-022-34408-0","article-title":"Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk","volume":"13","author":"Wang","year":"2022","unstructured":"Wang X, Nissen M, Gracias D, Kusakabe M, Simkin G, Jiang A, Duns G, Sarkozy C, Hilton L, Chavez EA, Segat GC, Wong R, Kim J, Aoki T, Islam R, May C, Hung S, Tyshchenko K, Brinkman RR, Hirst M, Karsan A, Freeman C, Sehn LH, Morin RD, Roth AJ, Savage KJ, Craig JW, Shah SP, Steidl C, Scott DW and Weng AP. Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk. Nat Commun 2022; 13: 6772.","journal-title":"Nat Commun"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/bs.ai.2021.05.002","article-title":"Follicular lymphoma dynamics","volume":"150","author":"Milpied","year":"2021","unstructured":"Milpied P, Gandhi AK, Cartron G, Pasqualucci L, Tarte K, Nadel B and Roulland S. Follicular lymphoma dynamics. Adv Immunol 2021; 150: 43-103.","journal-title":"Adv Immunol"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Gordon MJ, Smith MR and Nastoupil LJ. Follicular lymphoma: the long and winding road leading to your cure? Blood Rev 2023; 57: 100992.","DOI":"10.1016\/j.blre.2022.100992"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41408-024-01111-w","article-title":"Identification of genetic subtypes in follicular lymphoma","volume":"14","author":"Shelton","year":"2024","unstructured":"Shelton V, Detroja R, Liu T, Isaev K, Silva A, Passerini V, Bakhtiari M, Calvente L, Hong M, He MY, Modi S, Hershenfeld SA, Ludvigsen M, Madsen C, Hamilton-Dutoit S, d&#x2019;Amore FA, Brodtkorb M, Johnson NA, Baetz T, LeBrun D, Tobin JWD, Gandhi MK, Mungall AJ, Xu W, Ben-Neriah S, Steidl C, Delabie J, Tremblay-LeMay R, Jegede O, Weigert O, Kahl B, Evens AM and Kridel R. Identification of genetic subtypes in follicular lymphoma. Blood Cancer J 2024; 14: 128.","journal-title":"Blood Cancer J"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Lopez JM, Villalobos MS, Almela EG, Espuch JG, Mar&#xED;n Sanchez MDP and Sevilla IN. Endometrial follicular B lymphoma. Surgeries 2019; 1: 1-5.","DOI":"10.35702\/surg.10005"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Barrington SF and Trotman J. The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma. Lancet Haematol 2021; 8: e80-e93.","DOI":"10.1016\/S2352-3026(20)30365-3"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/bjh.17404","article-title":"The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma","volume":"195","author":"Barraclough","year":"2021","unstructured":"Barraclough A, Bishton M, Cheah CY, Villa D and Hawkes EA. The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma. Br J Haematol 2021; 195: 15-24.","journal-title":"Br J Haematol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.talanta.2018.10.086","article-title":"Raman spectroscopy discriminates malignant follicular lymphoma from benign follicular hyperplasia and from tumour metastasis","volume":"194","author":"Rau","year":"2019","unstructured":"Rau JV, Marini F, Fosca M, Cippitelli C, Rocchia M and Di Napoli A. Raman spectroscopy discriminates malignant follicular lymphoma from benign follicular hyperplasia and from tumour metastasis. Talanta 2019; 194: 763-770.","journal-title":"Talanta"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.humpath.2020.09.014","article-title":"The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma","volume":"106","author":"Barasch","year":"2020","unstructured":"Barasch NJK, Liu YC, Ho J, Bailey N, Aggarwal N, Cook JR and Swerdlow SH. The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma. Hum Pathol 2020; 106: 93-105.","journal-title":"Hum Pathol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.5858\/arpa.2018-0215-RA","article-title":"Primary cutaneous follicle center lymphoma","volume":"142","author":"SL","year":"2018","unstructured":"Skala SL, Hristov B and Hristov AC. Primary cutaneous follicle center lymphoma. Arch Pathol Lab Med 2018; 142: 1313-1321.","journal-title":"Arch Pathol Lab Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1182\/blood.V128.22.2979.2979","article-title":"Contempo: preliminary results in first-line treatment of follicular lymphoma with the oral dual PI3K-&#x3B4;, &#x3B3; inhibitor, duvelisib, in combination with rituximab or obinutuzumab","volume":"128","author":"Casulo","year":"2016","unstructured":"Casulo C, Sancho JM, Van Eygen K, de Vos S, Mercadal S, Johnson RJ, Bouabdallah K, Holmes H, Lemmens J and Gyan E. Contempo: preliminary results in first-line treatment of follicular lymphoma with the oral dual PI3K-&#x3B4;, &#x3B3; inhibitor, duvelisib, in combination with rituximab or obinutuzumab. Blood 2016; 128: 2979.","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/PAS.0000000000001609","article-title":"Biomarkers for risk stratification in patients with previously untreated follicular lymphoma receiving anti-CD20-based biological therapy","volume":"45","author":"Sohani","year":"2021","unstructured":"Sohani AR, Maurer MJ, Giri S, Pitcher B, Chadburn A, Said JW, Bartlett NL, Czuczman MS, Martin P, Rosenbaum CA, Jung SH, Leonard JP, Cheson BD and Hsi ED. Biomarkers for risk stratification in patients with previously untreated follicular lymphoma receiving anti-CD20-based biological therapy. Am J Surg Pathol 2021; 45: 384-393.","journal-title":"Am J Surg Pathol"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Ju&#xE1;rez-Salcedo LM, Conde-Royo D, Quiroz-Cervantes K and Dalia S. Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature. Drugs Context 2020; 9: 2019-9-3.","DOI":"10.7573\/dic.2019-9-3"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Laurent C, Cook JR, Yoshino T, Quintanilla-Martinez L and Jaffe ES. Follicular lymphoma and marginal zone lymphoma: how many diseases? Virchows Arch 2023; 482: 149-162.","DOI":"10.1007\/s00428-022-03432-2"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/cup.13765","article-title":"Small lymphocytic lymphoma mimicking primary cutaneous marginal zone lymphoma with colonization of germinal center follicles","volume":"48","author":"LeBlanc","year":"2021","unstructured":"LeBlanc RE, Carter JB, Kaur P and Lansigan F. Small lymphocytic lymphoma mimicking primary cutaneous marginal zone lymphoma with colonization of germinal center follicles. J Cutan Pathol 2021; 48: 72-76.","journal-title":"J Cutan Pathol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/cancers15030785","article-title":"Follicular lymphoma in the 5th edition of the WHO-classification of haematolymphoid neoplasms-updated classification and new biological data","volume":"15","author":"Kurz","year":"2023","unstructured":"Kurz KS, Kalmbach S, Ott M, Staiger AM, Ott G and Horn H. Follicular lymphoma in the 5th edition of the WHO-classification of haematolymphoid neoplasms-updated classification and new biological data. Cancers (Basel) 2023; 15: 785.","journal-title":"Cancers (Basel)"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"JW","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstr&#xF6;m-Lindberg E, Tefferi A and Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.","journal-title":"Blood"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L and Xiao W. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022; 36: 1720-1748.","journal-title":"Leukemia"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","unstructured":"Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A and Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016; 66: 443-459.","journal-title":"CA Cancer J Clin"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman AL, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles G, San-Miguel J, Seymour JF, Treon SP, Vose JM, Zucca E, Advani R, Ansell S, Au WY, Barrionuevo C, Bergsagel L, Chan WC, Cohen JI, d&#x2019;Amore F, Davies A, Falini B, Ghobrial IM, Goodlad JR, Gribben JG, Hsi ED, Kahl BS, Kim WS, Kumar S, LaCasce AS, Laurent C, Lenz G, Leonard JP, Link MP, Lopez-Guillermo A, Mateos MV, Macintyre E, Melnick AM, Morschhauser F, Nakamura S, Narbaitz M, Pavlovsky A, Pileri SA, Piris M, Pro B, Rajkumar V, Rosen ST, Sander B, Sehn L, Shipp MA, Smith SM, Staudt LM, Thieblemont C, Tousseyn T, Wilson WH, Yoshino T, Zinzani PL, Dreyling M, Scott DW, Winter JN and Zelenetz AD. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood 2022; 140: 1229-1253.","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Zoellner A, Herfarth K, Herold M, Klapper W, Skoetz N and Hiddemann W; The guideline group. Clinical practice guideline: follicular lymphoma-diagnosis, treatment, and follow-up. Dtsch Arztebl Int 2021; 118: 320-5.","DOI":"10.3238\/arztebl.m2021.0022"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","unstructured":"Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, J&#xE4;ger U, Cartron G, Izutsu K, Dreyling M, Kahl B, Ghesquieres H, Ardeshna K, Goto H, Barbui AM, Abramson JS, Borchmann P, Fleury I, Mielke S, Skarbnik A, de Vos S, Kamdar M, Karmali R, Viardot A, Farazi T, Fasan O, Lymp J, Vedal M, Nishii R, Avilion A, Papuga J, Kumar J and Nastoupil LJ. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med 2024; 30: 2199-2207.","journal-title":"Nat Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"772","DOI":"10.21037\/qims-20-1139","article-title":"The characteristic computed tomography findings of pulmonary B-cell non-Hodgkin&#x2019;s lymphoma and their role in predicting patient survival","volume":"11","author":"Wang","year":"2021","unstructured":"Wang Y, Pan ZC, Zhu L, Ma YY, Zhang MC, Wang L, Zhao WL, Yan FH and Song Q. The characteristic computed tomography findings of pulmonary B-cell non-Hodgkin&#x2019;s lymphoma and their role in predicting patient survival. Quant Imaging Med Surg 2021; 11: 772-783.","journal-title":"Quant Imaging Med Surg"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11282-021-00582-y","article-title":"A retrospective study to evaluate the CT and MR imaging findings of non-Hodgkin&#x2019;s lymphoma affecting the jaw bones","volume":"38","author":"Liu","year":"2022","unstructured":"Liu Y, Wang Y, Wang P and Yu Q. A retrospective study to evaluate the CT and MR imaging findings of non-Hodgkin&#x2019;s lymphoma affecting the jaw bones. Oral Radiol 2022; 38: 509-516.","journal-title":"Oral Radiol"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Jia Q, Wang A, Liu Y, Fan Y, Zhou X, Liu Y, Wu L, Ouyang X, Su J, Shi B and Liu X. Diagnostic value of baseline 18F-FDG PET\/CT and peripheral blood inflammatory markers for aggressive lymphoma in non-Hodgkin&#x2019;s lymphoma. Nucl Med Commun 2024; [Epub ahead of print].","DOI":"10.1097\/MNM.0000000000001912"},{"key":"ref51","unstructured":"Mitamura K, Norikane T, Yamamoto Y, Ihara-Nishishita A, Kobata T, Fujimoto K, Takami Y, Kudomi N, Hoshikawa H and Nishiyama Y. Texture indices of 18F-FDG PET\/CT for differentiating squamous cell carcinoma and non-Hodgkin&#x2019;s lymphoma of the oropharynx. Acta Med Okayama 2021; 75: 351-356."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1080\/10428194.2021.1984450","article-title":"Persistent fatigue among long-term non-Hodgkin lymphoma survivors","volume":"63","author":"LeBlanc","year":"2022","unstructured":"LeBlanc MR, Zimmerman S, LeBlanc TW, Bryant AL, Hudson KE and Smith SK. Persistent fatigue among long-term non-Hodgkin lymphoma survivors. Leuk Lymphoma 2022; 63: 344-352.","journal-title":"Leuk Lymphoma"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.1007\/s00520-021-06246-1","article-title":"Exploring health-related quality of life among non-Hodgkin&#x2019;s lymphoma survivors after completion of primary treatment: a cross-sectional study in Thailand","volume":"29","author":"Lekdamrongkul","year":"2021","unstructured":"Lekdamrongkul P, Pongthavornkamol K, Molassiotis A, Sriyuktasuth A, Siritanaratkul N and Chansatitporn N. Exploring health-related quality of life among non-Hodgkin&#x2019;s lymphoma survivors after completion of primary treatment: a cross-sectional study in Thailand. Support Care Cancer 2021; 29: 6511-6522.","journal-title":"Support Care Cancer"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3390\/jpm11030215","article-title":"Body composition change, unhealthy lifestyles and steroid treatment as predictor of metabolic risk in non-Hodgkin&#x2019;s lymphoma survivors","volume":"11","author":"Daniele","year":"2021","unstructured":"Daniele A, Guarini A, Summa S, Dellino M, Lerario G, Ciavarella S, Ditonno P, Paradiso AV, Divella R, Casamassima P, Savino E, Carbonara MD and Minoia C. Body composition change, unhealthy lifestyles and steroid treatment as predictor of metabolic risk in non-Hodgkin&#x2019;s lymphoma survivors. J Pers Med 2021; 11: 215.","journal-title":"J Pers Med"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40170-023-00327-x","article-title":"The classification of obesity based on metabolic status redefines the readmission of non-Hodgkin&#x2019;s lymphoma-an observational study","volume":"11","author":"Dong","year":"2023","unstructured":"Dong H, Guo H, Du J, Cheng Y, Wang D, Han J, Yuan Z, Yao Z, An R, Wu X, Poulsen KL, Wang Z, Shao S, Fan X, Wang Z and Zhao J. The classification of obesity based on metabolic status redefines the readmission of non-Hodgkin&#x2019;s lymphoma-an observational study. Cancer Metab 2023; 11: 24.","journal-title":"Cancer Metab"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Wu M, Wulipan F, Ma J, Qian W, Sun S, Chen P, Xu Y, Chen M, Yang W, Xie Y and Shen L. Clinical characteristics and prognostic factors of lymphoma patients initially presenting with fever of unknown origin. Am J Transl Res 2022; 14: 2625-2636.","DOI":"10.21203\/rs.3.rs-847421\/v1"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.5306\/wjco.v15.i8.1110","article-title":"Non-Hodgkin&#x2019;s lymphoma involving chronic difficult-to-heal wounds: a case report","volume":"15","author":"Zhang","year":"2024","unstructured":"Zhang PS, Wang R, Wu HW, Zhou H, Deng HB, Fan WX, Li JC and Cheng SW. Non-Hodgkin&#x2019;s lymphoma involving chronic difficult-to-heal wounds: a case report. World J Clin Oncol 2024; 15: 1110-1116.","journal-title":"World J Clin Oncol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"581","DOI":"10.4103\/apjon.apjon-2119","article-title":"Nursing of a non-Hodgkin&#x2019;s lymphoma patient with a facial malignant fungating wound","volume":"8","author":"You","year":"2021","unstructured":"You M, Zhang S, Ma X, Liu H, Lu Y and Li Y. Nursing of a non-Hodgkin&#x2019;s lymphoma patient with a facial malignant fungating wound. Asia Pac J Oncol Nurs 2021; 8: 581-585.","journal-title":"Asia Pac J Oncol Nurs"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Khan QA, Mumtaz A, Baqi A, Ain HU, Mahfooz RS, Asim N, Iram S, Hussien Mohamed Ahmed KA, Tahir MJ and Yousaf Z. Non-Hodgkin&#x2019;s lymphoma masquerading as splenic abscess: a case report. Ann Med Surg (Lond) 2022; 81: 104449.","DOI":"10.1016\/j.amsu.2022.104449"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.7314\/APJCP.2015.16.8.3551","article-title":"Signs, symptoms and complications of non-Hodgkin&#x2019;s lymphoma according to grade and stage in South Iran","volume":"16","author":"Dehghani","year":"2015","unstructured":"Dehghani M, Haddadi S and Vojdani R. Signs, symptoms and complications of non-Hodgkin&#x2019;s lymphoma according to grade and stage in South Iran. Asian Pac J Cancer Prev 2015; 16: 3551-7.","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3389\/fimmu.2020.00149","article-title":"Non-infectious complications of common variable immunodeficiency: updated clinical spectrum, sequelae, and insights to pathogenesis","volume":"11","author":"HE","year":"2020","unstructured":"Ho HE and Cunningham-Rundles C. Non-infectious complications of common variable immunodeficiency: updated clinical spectrum, sequelae, and insights to pathogenesis. Front Immunol 2020; 11: 149.","journal-title":"Front Immunol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"4484","DOI":"10.62347\/BTGQ7302","article-title":"Interstitial pneumonia development after chemotherapy in B-cell non-Hodgkin&#x2019;s lymphoma patients: clinical profiles and risk factors","volume":"14","author":"Ma","year":"2024","unstructured":"Ma R, Li Y, Yin S, Gao Y and Zhao G. Interstitial pneumonia development after chemotherapy in B-cell non-Hodgkin&#x2019;s lymphoma patients: clinical profiles and risk factors. Am J Cancer Res 2024; 14: 4484-4494.","journal-title":"Am J Cancer Res"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"106267","DOI":"10.1016\/j.leukres.2019.106267","article-title":"Cytofluorimetric and immunohistochemical comparison for detecting bone marrow infiltration in non-Hodgkin lymphomas: a study of 354 patients","volume":"88","author":"Statuto","year":"2020","unstructured":"Statuto T, Valvano L, Calice G, Villani O, Pietrantuono G, Mansueto G, D&#x2019;Arena G, Vita G, Lalinga V, Possidente L, Del Vecchio L, D&#x2019;Auria F and Musto P. Cytofluorimetric and immunohistochemical comparison for detecting bone marrow infiltration in non-Hodgkin lymphomas: a study of 354 patients. Leuk Res 2020; 88: 106267.","journal-title":"Leuk Res"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Sawaftah Z, Awashra A, Bani Odah A, Sawafta A, Alawna A, Khamaysa J, Abdalqader M and Ghannam Y. A persistent pulmonary puzzle: diagnosing Hodgkin lymphoma in a young female with chronic respiratory symptoms. Cureus 2024; 16: e65569.","DOI":"10.7759\/cureus.65569"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"3946320241264369","DOI":"10.1177\/03946320241264369","article-title":"Non-neoplastic B-cell predominant lymphoid proliferations at the organs exposed to external environment mimicking lymphoma: a potential diagnostic pitfall","volume":"38","author":"Fan","year":"2024","unstructured":"Fan Y, Thong BKS, Binshen O, Shen X, Yi H and Wang C. Non-neoplastic B-cell predominant lymphoid proliferations at the organs exposed to external environment mimicking lymphoma: a potential diagnostic pitfall. Int J Immunopathol Pharmacol 2024; 38: 3946320241264369.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3390\/diagnostics13050861","article-title":"Metabolomics: a new era in the diagnosis or prognosis of B-cell non-Hodgkin&#x2019;s lymphoma","volume":"13","author":"Alfaifi","year":"2023","unstructured":"Alfaifi A, Refai MY, Alsaadi M, Bahashwan S, Malhan H, Al-Kahiry W, Dammag E, Ageel A, Mahzary A, Albiheyri R, Almehdar H and Qadri I. Metabolomics: a new era in the diagnosis or prognosis of B-cell non-Hodgkin&#x2019;s lymphoma. Diagnostics (Basel) 2023; 13: 861.","journal-title":"Diagnostics (Basel)"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Wei DH, Peng YK and Liu W. Duodenal-type follicular lymphoma. Am J Med Sci 2023; 366: e5.","DOI":"10.1016\/j.amjms.2023.03.013"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1090610","DOI":"10.3389\/fonc.2023.1090610","article-title":"The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma","volume":"13","author":"Hu","year":"2023","unstructured":"Hu J, Gao F, Zhao J, Song W, Wang Y, Zheng Y, Wang L, Han W, Ma L, Wang J, Bai M, Guan T, Xi Y, Zhang H, Qiu L and Su L. The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma. Front Oncol 2023; 13: 1090610.","journal-title":"Front Oncol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1273719","DOI":"10.3389\/fonc.2023.1273719","article-title":"An adolescent with primary cutaneous follicle center lymphoma: a case report and literature review","volume":"13","author":"Niu","year":"2023","unstructured":"Niu WY, Yan XS, Qiao H, Sun YJ, Gu HY, Li GL, Cui ZG and Du J. An adolescent with primary cutaneous follicle center lymphoma: a case report and literature review. Front Oncol 2023; 13: 1273719.","journal-title":"Front Oncol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5045\/br.2022.2022037","article-title":"Basic immunohistochemistry for lymphoma diagnosis","volume":"57","author":"Cho","year":"2022","unstructured":"Cho J. Basic immunohistochemistry for lymphoma diagnosis. Blood Res 2022; 57: 55-61.","journal-title":"Blood Res"},{"key":"ref71","unstructured":"Huang Y, Hu S and Cui WT. Relationships between CASP8, fas gene polymorphisms and the prognosis of patients with non-Hodgkin&#x2019;s lymphoma in Han Nationality. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021; 29: 1493-1497."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"5687","DOI":"10.2147\/JIR.S329090","article-title":"Genetic polymorphisms in NLRP3 inflammasome-associated genes in patients with B-cell non-Hodgkin&#x2019;s lymphoma","volume":"14","author":"Liu","year":"2021","unstructured":"Liu ZH, Zhang L, Jing FJ, Xiao SX, Gao Y, Bian HY and Zhao X. Genetic polymorphisms in NLRP3 inflammasome-associated genes in patients with B-cell non-Hodgkin&#x2019;s lymphoma. J Inflamm Res 2021; 14: 5687-5697.","journal-title":"J Inflamm Res"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00428-019-02681-y","article-title":"Novel markers in pediatric-type follicular lymphoma","volume":"475","author":"Agostinelli","year":"2019","unstructured":"Agostinelli C, Akarca AU, Ramsay A, Rizvi H, Rodriguez-Justo M, Pomplun S, Proctor I, Sabattini E, Linch D, Daw S, Pittaluga S, Pileri SA, Jaffe ES, Quintanilla-Martinez L and Marafioti T. Novel markers in pediatric-type follicular lymphoma. Virchows Arch 2019; 475: 771-779.","journal-title":"Virchows Arch"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/pin.13223","article-title":"Clinicopathological analysis of follicular lymphoma with BCL2, BCL6, and MYC rearrangements","volume":"72","author":"Ikoma","year":"2022","unstructured":"Ikoma H, Miyaoka M, Hiraiwa S, Yukie Kikuti Y, Shiraiwa S, Hara R, Kojima M, Ohmachi K, Ando K, Carreras J and Nakamura N. Clinicopathological analysis of follicular lymphoma with BCL2, BCL6, and MYC rearrangements. Pathol Int 2022; 72: 321-331.","journal-title":"Pathol Int"},{"key":"ref75","unstructured":"Guo MQ, Luo XY, Wu HY and Huang YX. Research progress of oral BCL-2 inhibitor venetoclax in the treatment of non-Hodgkin&#x2019;s lymphoma--review. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2022; 30: 1622-1626."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2020.09.016","article-title":"Decreased BIM expression in BCL2-negative follicular lymphoma: a potential mechanism for resistance to apoptosis","volume":"107","author":"Socha","year":"2021","unstructured":"Socha DS, Zhao X, Bodo J, Durkin L and Hsi ED. Decreased BIM expression in BCL2-negative follicular lymphoma: a potential mechanism for resistance to apoptosis. Hum Pathol 2021; 107: 1-8.","journal-title":"Hum Pathol"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Zhu Z, Li T, Zhang X, Zhang Z, Zhu D, Lin P, Tu S and Ren W. Molecular and clinical progress in follicular lymphoma lacking the t(14;18) translocation (Review). Int J Oncol 2020; 56: 7-17.","DOI":"10.3892\/ijo.2019.4917"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Alnaim AF, Alhawsawi A, AlSomali A, Jannadi R, Alsolami SM and Alotaibi HA. Conjunctival pediatric-type follicular lymphoma in a young male: a case report and literature review. Cureus 2022; 14: e22023.","DOI":"10.7759\/cureus.22023"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"109793","DOI":"10.1016\/j.ejrad.2021.109793","article-title":"Overview and recent advances in PET\/CT imaging in lymphoma and multiple myeloma","volume":"141","author":"Zanoni","year":"2021","unstructured":"Zanoni L, Mattana F, Calabr&#xF2; D, Paccagnella A, Broccoli A, Nanni C and Fanti S. Overview and recent advances in PET\/CT imaging in lymphoma and multiple myeloma. Eur J Radiol 2021; 141: 109793.","journal-title":"Eur J Radiol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12885-020-07723-2","article-title":"Evaluation of 18F-FDG PET\/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph vision","volume":"21","author":"Weber","year":"2021","unstructured":"Weber M, Jentzen W, Hofferber R, Herrmann K, Fendler WP, Rischpler C, Umutlu L, Conti M, Costa PF, Sraieb M and Kersting D. Evaluation of 18F-FDG PET\/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph vision. BMC Cancer 2021; 21: 62.","journal-title":"BMC Cancer"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"100440","DOI":"10.1016\/j.modpat.2024.100440","article-title":"Follicular lymphoma presenting with symptomatic bone involvement: a clinicopathologic and molecular analysis of 16 cases","volume":"37","author":"Sarro","year":"2024","unstructured":"Sarro R, Bisig B, Guey B, Missiaglia E, Cairoli A, Omoumi P, Letovanec I, Ferry JA, Hasserjian RP and de Leval L. Follicular lymphoma presenting with symptomatic bone involvement: a clinicopathologic and molecular analysis of 16 cases. Mod Pathol 2024; 37: 100440.","journal-title":"Mod Pathol"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Jahanshahi A, Hiradfar A, Zarrintan A and Mirza-Aghazadeh-Attari M. Primary pleural lymphoma of T cell origin in a paediatric patient with a focus on radiological findings - a case report and review of literature. Pol J Radiol 2019; 84: e353-e359.","DOI":"10.5114\/pjr.2019.88773"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/hon.2676","article-title":"Whole-body magnetic resonance imaging (WB-MRI) in lymphoma: state of the art","volume":"38","author":"Albano","year":"2020","unstructured":"Albano D, Bruno A, Patti C, Micci G, Midiri M, Tarella C and Galia M. Whole-body magnetic resonance imaging (WB-MRI) in lymphoma: state of the art. Hematol Oncol 2020; 38: 12-21.","journal-title":"Hematol Oncol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.radcr.2023.05.041","article-title":"Follicular lymphoma presenting as a seminal vesicle mass: diagnostic path from prostate MRI to 18F-FDG PET\/CT","volume":"18","author":"Ucpinar","year":"2023","unstructured":"Ucpinar BA, Reese S, Eismann L and Aras O. Follicular lymphoma presenting as a seminal vesicle mass: diagnostic path from prostate MRI to 18F-FDG PET\/CT. Radiol Case Rep 2023; 18: 2768-2770.","journal-title":"Radiol Case Rep"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40644-020-00371-6","article-title":"Assessment of naive indolent lymphoma using whole-body diffusion-weighted imaging and T2-weighted MRI: results of a prospective study in 30 patients","volume":"21","author":"Hong","year":"2021","unstructured":"Hong GS, Chae EJ, Ryu JS, Chae SY, Lee HS, Yoon DH and Suh C. Assessment of naive indolent lymphoma using whole-body diffusion-weighted imaging and T2-weighted MRI: results of a prospective study in 30 patients. Cancer Imaging 2021; 21: 5.","journal-title":"Cancer Imaging"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1634\/theoncologist.2019-0952","article-title":"Fluorodeoxyglucose-positron emission tomography predicts bone marrow involvement in the staging of follicular lymphoma","volume":"25","author":"St-Pierre","year":"2020","unstructured":"St-Pierre F, Broski SM, LaPlant BR, Maurer MJ, Ristow K, Thanarajasingam G, Macon WR, Habermann TM and Witzig TE. Fluorodeoxyglucose-positron emission tomography predicts bone marrow involvement in the staging of follicular lymphoma. Oncologist 2020; 25: 689-695.","journal-title":"Oncologist"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/bjh.18974","article-title":"Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma","volume":"202","author":"Gao","year":"2023","unstructured":"Gao F, Liu H, Meng X, Liu J, Wang J, Yu J, Liu X, Liu X, Li L, Qiu L, Qian Z, Zhou S, Gong W, Meng B, Ren X, Golchehre Z, Chavoshzadeh Z, He J, Zhang H and Wang X. Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma. Br J Haematol 2023; 202: 1151-1164.","journal-title":"Br J Haematol"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Asmann YW, Maurer MJ, Wang C, Sarangi V, Ansell SM, Feldman AL, Nowakowski GS, Manske M, Price-Troska T, Yang ZZ, Slager SL, Habermann TM, Cerhan JR and Novak AJ. Genetic diversity of newly diagnosed follicular lymphoma. Blood Cancer J 2014; 4: e256.","DOI":"10.1038\/bcj.2014.80"},{"key":"ref89","unstructured":"Carreras J, Hamoudi R and Nakamura N. Artificial intelligence analysis of gene expression data predicted the prognosis of patients with diffuse large B-cell lymphoma. Tokai J Exp Clin Med 2020; 45: 37-48."},{"key":"ref90","doi-asserted-by":"publisher","first-page":"705010","DOI":"10.3389\/fonc.2021.705010","article-title":"Personally tailored survival prediction of patients with follicular lymphoma using machine learning transcriptome-based models","volume":"11","author":"Orgueira A","year":"2022","unstructured":"Mosquera Orgueira A, Cid L&#xF3;pez M, Peleteiro Ra&#xED;ndo A, Abu&#xED;n Blanco A, D&#xED;az Arias J&#xC1;, Gonz&#xE1;lez P&#xE9;rez MS, Antelo Rodr&#xED;guez B, Bao P&#xE9;rez L, Ferreiro Ferro R, Aliste Santos C, P&#xE9;rez Encinas MM, Fraga Rodr&#xED;guez MF, Cerchione C, Mozas P and Bello L&#xF3;pez JL. Personally tailored survival prediction of patients with follicular lymphoma using machine learning transcriptome-based models. Front Oncol 2022; 11: 705010.","journal-title":"Front Oncol"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1182\/blood-2017-07-737353","article-title":"The promises and challenges of using gene mutations for patient stratification in follicular lymphoma","volume":"130","author":"Weigert","year":"2017","unstructured":"Weigert O and Weinstock DM. The promises and challenges of using gene mutations for patient stratification in follicular lymphoma. Blood 2017; 130: 1491-1498.","journal-title":"Blood"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/cancers13040641","article-title":"Follicular lymphoma microenvironment: an intricate network ready for therapeutic intervention","volume":"13","author":"Doba&#xF1","year":"2021","unstructured":"Doba&#xF1;o-L&#xF3;pez C, Araujo-Ayala F, Serrat N, Valero JG and P&#xE9;rez-Gal&#xE1;n P. Follicular lymphoma microenvironment: an intricate network ready for therapeutic intervention. Cancers (Basel) 2021; 13: 641.","journal-title":"Cancers (Basel)"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.1073\/pnas.1701263114","article-title":"Functional proteogenomics reveals biomarkers and therapeutic targets in lymphomas","volume":"114","author":"Rolland","year":"2017","unstructured":"Rolland DCM, Basrur V, Jeon YK, McNeil-Schwalm C, Fermin D, Conlon KP, Zhou Y, Ng SY, Tsou CC, Brown NA, Thomas DG, Bailey NG, Omenn GS, Nesvizhskii AI, Root DE, Weinstock DM, Faryabi RB, Lim MS and Elenitoba-Johnson KSJ. Functional proteogenomics reveals biomarkers and therapeutic targets in lymphomas. Proc Natl Acad Sci U S A 2017; 114: 6581-6586.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Coccaro N, Anelli L, Zagaria A, Perrone T, Specchia G and Albano F. Molecular complexity of diffuse large B-cell lymphoma: can it be a roadmap for precision medicine? Cancers (Basel) 2020; 12: 185.","DOI":"10.3390\/cancers12010185"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/modpathol.2017.134","article-title":"Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements","volume":"31","author":"Miyaoka","year":"2018","unstructured":"Miyaoka M, Kikuti YY, Carreras J, Ikoma H, Hiraiwa S, Ichiki A, Kojima M, Ando K, Yokose T, Sakai R, Hoshikawa M, Tomita N, Miura I, Takata K, Yoshino T, Takizawa J, Bea S, Campo E and Nakamura N. Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements. Mod Pathol 2018; 31: 313-326.","journal-title":"Mod Pathol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1182\/blood-2016-03-703819","article-title":"Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene","volume":"128","author":"Schmidt","year":"2016","unstructured":"Schmidt J, Gong S, Marafioti T, Mankel B, Gonzalez-Farre B, Balagu&#xE9; O, Mozos A, Cabe&#xE7;adas J, van der Walt J, Hoehn D, Rosenwald A, Ott G, Dojcinov S, Egan C, Nadeu F, Ramis-Zald&#xED;var JE, Clot G, B&#xE1;rcena C, P&#xE9;rez-Alonso V, Endris V, Penzel R, Lome-Maldonado C, Bonzheim I, Fend F, Campo E, Jaffe ES, Salaverria I and Quintanilla-Martinez L. Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood 2016; 128: 1101-1111.","journal-title":"Blood"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.pathol.2019.09.010","article-title":"Pathology and diagnosis of follicular lymphoma and related entities","volume":"52","author":"Randall","year":"2020","unstructured":"Randall C and Fedoriw Y. Pathology and diagnosis of follicular lymphoma and related entities. Pathology 2020; 52: 30-39.","journal-title":"Pathology"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/his.13316","article-title":"MYC expression and translocation analyses in low-grade and transformed follicular lymphoma","volume":"71","author":"Aukema","year":"2017","unstructured":"Aukema SM, van Pel R, Nagel I, Bens S, Siebert R, Rosati S, van den Berg E, Bosga-Bouwer AG, Kibbelaar RE, Hoogendoorn M, van Imhoff GW, Kluin-Nelemans HC, Kluin PM and Nijland M. MYC expression and translocation analyses in low-grade and transformed follicular lymphoma. Histopathology 2017; 71: 960-971.","journal-title":"Histopathology"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"1205384","DOI":"10.3389\/fped.2023.1205384","article-title":"Case report: clinicopathological and molecular characteristics of pediatric-type follicular lymphoma","volume":"11","author":"Ren","year":"2023","unstructured":"Ren B, Chen Y, Bai X, Zheng J, Chang J, Jiang X, Xia Q and Zhang H. Case report: clinicopathological and molecular characteristics of pediatric-type follicular lymphoma. Front Pediatr 2023; 11: 1205384.","journal-title":"Front Pediatr"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Gonz&#xE1;lez-Rinc&#xF3;n J, M&#xE9;ndez M, G&#xF3;mez S, Garc&#xED;a JF, Mart&#xED;n P, Bellas C, Pedrosa L, Rodr&#xED;guez-Pinilla SM, Camacho FI, Quero C, P&#xE9;rez-Callejo D, Rueda A, Llanos M, G&#xF3;mez-Codina J, Piris MA, Montes-Moreno S, B&#xE1;rcena C, Rodr&#xED;guez-Abreu D, Men&#xE1;rguez J, de la Cruz-Merino L, Monsalvo S, Parejo C, Royuela A, Kwee I, Cascione L, Arribas A, Bertoni F, Mollejo M, Provencio M and S&#xE1;nchez-Beato M. Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. PLoS One 2019; 14: e0212813.","DOI":"10.1371\/journal.pone.0212813"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2478\/raon-2023-0030","article-title":"Correlation of t(14;18) translocation breakpoint site with clinical characteristics in follicular lymphoma","volume":"57","author":"Panjan","year":"2023","unstructured":"Panjan M, Boltezar L, Novakovic S, Kokovic I and Jezersek Novakovic B. Correlation of t(14;18) translocation breakpoint site with clinical characteristics in follicular lymphoma. Radiol Oncol 2023; 57: 487-492.","journal-title":"Radiol Oncol"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3960\/jslrt.22030","article-title":"MYC\/BCL2 double- and MYC\/BCL2\/BCL6 triple-hit follicular lymphomas associated with t(8;14;18)(q24;q32;q21)","volume":"62","author":"Takeoka","year":"2022","unstructured":"Takeoka K, Maekawa F, Nakagawa M, Kishimori C, Fukutsuka K, Hayashida M, Sumiyoshi S and Ohno H. MYC\/BCL2 double- and MYC\/BCL2\/BCL6 triple-hit follicular lymphomas associated with t(8;14;18)(q24;q32;q21). J Clin Exp Hematop 2022; 62: 258-267.","journal-title":"J Clin Exp Hematop"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1080\/10428194.2024.2341333","article-title":"Two recurrent types of IGH::5&#x2019; BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the VDJ and class switch recombination processes, respectively","volume":"65","author":"Maekawa","year":"2024","unstructured":"Maekawa F, Hayashida M, Takeoka K, Fukutsuka K, Nakagawa M, Akasaka T, Sakamoto S, Sumiyoshi S, Kobashi Y and Ohno H. Two recurrent types of IGH::5&#x2019; BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the VDJ and class switch recombination processes, respectively. Leuk Lymphoma 2024; 65: 1100-1109.","journal-title":"Leuk Lymphoma"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1053\/j.seminoncol.2018.07.005","article-title":"New concepts in follicular lymphoma biology: from BCL2 to epigenetic regulators and non-coding RNAs","volume":"45","author":"Devan","year":"2018","unstructured":"Devan J, Janikova A and Mraz M. New concepts in follicular lymphoma biology: from BCL2 to epigenetic regulators and non-coding RNAs. Semin Oncol 2018; 45: 291-302.","journal-title":"Semin Oncol"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13046-021-02234-9","article-title":"The follicular lymphoma epigenome regulates its microenvironment","volume":"41","author":"Amin","year":"2022","unstructured":"Amin R and Braza MS. The follicular lymphoma epigenome regulates its microenvironment. J Exp Clin Cancer Res 2022; 41: 21.","journal-title":"J Exp Clin Cancer Res"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1182\/bloodadvances.2020002944","article-title":"Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease","volume":"4","author":"Nann","year":"2020","unstructured":"Nann D, Ramis-Zaldivar JE, M&#xFC;ller I, Gonzalez-Farre B, Schmidt J, Egan C, Salmeron-Villalobos J, Clot G, Mattern S, Otto F, Mankel B, Colomer D, Balagu&#xE9; O, Szablewski V, Lome-Maldonado C, Leoncini L, Dojcinov S, Chott A, Copie-Bergman C, Bonzheim I, Fend F, Jaffe ES, Campo E, Salaverria I and Quintanilla-Martinez L. Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. Blood Adv 2020; 4: 5652-5665.","journal-title":"Blood Adv"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/jha2.28","article-title":"Relapse of follicular lymphoma arising from a non-t(14;18) clone","volume":"1","author":"Otsuka","year":"2020","unstructured":"Otsuka Y, Nishikori M, Fujimoto M, Nakao K, Hishizawa M, Haga H and Takaori-Kondo A. Relapse of follicular lymphoma arising from a non-t(14;18) clone. EJHaem 2020; 1: 323-327.","journal-title":"EJHaem"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.imlet.2023.08.007","article-title":"Immune dysregulation as a leading principle for lymphoma development in diverse immunological backgrounds","volume":"263","author":"Kolijn","year":"2023","unstructured":"Kolijn PM and Langerak AW. Immune dysregulation as a leading principle for lymphoma development in diverse immunological backgrounds. Immunol Lett 2023; 263: 46-59.","journal-title":"Immunol Lett"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/DAD.0000000000001547","article-title":"Follicular eruption with folliculotropic lymphocytic infiltrates associated with iatrogenic immunosuppression: report and study of 3 cases, and review of the literature","volume":"42","author":"Avitan-Hersh","year":"2020","unstructured":"Avitan-Hersh E, Dias-Polak D, Ramon M, Sahar D, Magen D, Pollack S and Bergman R. Follicular eruption with folliculotropic lymphocytic infiltrates associated with iatrogenic immunosuppression: report and study of 3 cases, and review of the literature. Am J Dermatopathol 2020; 42: 498-505.","journal-title":"Am J Dermatopathol"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.3390\/ijms22105352","article-title":"The tumor microenvironment in follicular lymphoma: its pro-malignancy role with therapeutic potential","volume":"22","author":"Watanabe","year":"2021","unstructured":"Watanabe T. The tumor microenvironment in follicular lymphoma: its pro-malignancy role with therapeutic potential. Int J Mol Sci 2021; 22: 5352.","journal-title":"Int J Mol Sci"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.hoc.2020.02.007","article-title":"Immunomodulatory agents in follicular lymphoma","volume":"34","author":"Ysebaert","year":"2020","unstructured":"Ysebaert L and Morschhauser F. Immunomodulatory agents in follicular lymphoma. Hematol Oncol Clin North Am 2020; 34: 715-726.","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"17202","DOI":"10.1038\/s41598-019-53163-9","article-title":"De novo cancer incidence after kidney and liver transplantation: results from a nationwide population based data","volume":"9","author":"Park","year":"2019","unstructured":"Park B, Yoon J, Choi D, Kim HJ, Jung YK, Kwon OJ and Lee KG. De novo cancer incidence after kidney and liver transplantation: results from a nationwide population based data. Sci Rep 2019; 9: 17202.","journal-title":"Sci Rep"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.3390\/ijms23063368","article-title":"Effects of B-cell lymphoma on the immune system and immune recovery after treatment: the paradigm of targeted therapy","volume":"23","author":"Mancuso","year":"2022","unstructured":"Mancuso S, Mattana M, Carlisi M, Santoro M and Siragusa S. Effects of B-cell lymphoma on the immune system and immune recovery after treatment: the paradigm of targeted therapy. Int J Mol Sci 2022; 23: 3368.","journal-title":"Int J Mol Sci"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.leukres.2018.11.004","article-title":"Systemic lupus erythematosus and lymphoma: incidence, pathogenesis and biology","volume":"75","author":"Klein","year":"2018","unstructured":"Klein A, Polliack A and Gafter-Gvili A. Systemic lupus erythematosus and lymphoma: incidence, pathogenesis and biology. Leuk Res 2018; 75: 45-49.","journal-title":"Leuk Res"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1093\/rheumatology\/kez011","article-title":"Bidirectional relationship between systemic lupus erythematosus and non-Hodgkin&#x2019;s lymphoma: a nationwide population-based study","volume":"58","author":"Wang","year":"2019","unstructured":"Wang LH, Wang WM, Lin SH and Shieh CC. Bidirectional relationship between systemic lupus erythematosus and non-Hodgkin&#x2019;s lymphoma: a nationwide population-based study. Rheumatology (Oxford) 2019; 58: 1245-1249.","journal-title":"Rheumatology (Oxford)"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"108386","DOI":"10.1016\/j.mrrev.2021.108386","article-title":"Genetic predisposition to lymphomas: overview of rare syndromes and inherited familial variants","volume":"788","author":"Szmyd","year":"2021","unstructured":"Szmyd B, Mlynarski W and Pastorczak A. Genetic predisposition to lymphomas: overview of rare syndromes and inherited familial variants. Mutat Res Rev Mutat Res 2021; 788: 108386.","journal-title":"Mutat Res Rev Mutat Res"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"110887","DOI":"10.1016\/j.envres.2021.110887","article-title":"A systematic review and meta-analysis of occupational exposures and risk of follicular lymphoma","volume":"197","author":"Odutola","year":"2021","unstructured":"Odutola MK, Benke G, Fritschi L, Giles GG, van Leeuwen MT and Vajdic CM. A systematic review and meta-analysis of occupational exposures and risk of follicular lymphoma. Environ Res 2021; 197: 110887.","journal-title":"Environ Res"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11864-018-0550-0","article-title":"Follicular lymphoma: past, present, and future","volume":"19","author":"Becnel","year":"2018","unstructured":"Becnel MR and Nastoupil LJ. Follicular lymphoma: past, present, and future. Curr Treat Options Oncol 2018; 19: 32.","journal-title":"Curr Treat Options Oncol"},{"key":"ref119","doi-asserted-by":"publisher","unstructured":"Casulo C, Larson MC, Lunde JJ, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan J, Flowers CR, Link BK and Maurer MJ. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol 2022; 9: e289-e300.","DOI":"10.1016\/S2352-3026(22)00033-3"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40487-021-00161-5","article-title":"Early relapse in first-line follicular lymphoma: a review of the clinical implications and available mitigation and management strategies","volume":"9","author":"Rodgers","year":"2021","unstructured":"Rodgers TD, Casulo C, Boissard F, Launonen A, Parreira J and Cartron G. Early relapse in first-line follicular lymphoma: a review of the clinical implications and available mitigation and management strategies. Oncol Ther 2021; 9: 329-346.","journal-title":"Oncol Ther"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.bbmt.2016.04.014","article-title":"Reduced-intensity conditioning with fludarabine, cyclophosphamide, and high-dose rituximab for allogeneic hematopoietic cell transplantation for follicular lymphoma: a phase two multicenter trial from the blood and marrow transplant clinical trials network","volume":"22","author":"GG","year":"2016","unstructured":"Laport GG, Wu J, Logan B, Bachanova V, Hosing C, Fenske T, Longo W, Devine SM, Nademanee A, Gersten I, Horowitz M, Lazarus HM and Riches ML; Blood and Marrow Transplant Clinical Trials Network. Reduced-intensity conditioning with fludarabine, cyclophosphamide, and high-dose rituximab for allogeneic hematopoietic cell transplantation for follicular lymphoma: a phase two multicenter trial from the blood and marrow transplant clinical trials network. Biol Blood Marrow Transplant 2016; 22: 1440-1448.","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1002\/cam4.2174","article-title":"Activated hippo signal pathway inhibits cell proliferation and promotes apoptosis in NK\/T cell lymphoma cells","volume":"8","author":"Chang","year":"2019","unstructured":"Chang Y, Fu XR, Cui M, Li WM, Zhang L, Li X, Li L, Sun ZC, Zhang XD, Li ZM, You XY, Nan FF, Wu JJ, Wang XH and Zhang MZ. Activated hippo signal pathway inhibits cell proliferation and promotes apoptosis in NK\/T cell lymphoma cells. Cancer Med 2019; 8: 3892-3904.","journal-title":"Cancer Med"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","unstructured":"Sarkozy C, Maurer MJ, Link BK, Ghesquieres H, Nicolas E, Thompson CA, Traverse-Glehen A, Feldman AL, Allmer C, Slager SL, Ansell SM, Habermann TM, Bachy E, Cerhan JR and Salles G. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol 2019; 37: 144-152.","journal-title":"J Clin Oncol"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/bjh.15708","article-title":"Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era","volume":"184","author":"Rivas-Delgado A","year":"2019","unstructured":"Rivas-Delgado A, Magnano L, Moreno-Vel&#xE1;zquez M, Garc&#xED;a O, Nadeu F, Mozas P, Dlouhy I, Baumann T, Rovira J, Gonz&#xE1;lez-Farre B, Mart&#xED;nez A, Balague O, Delgado J, Villamor N, Gin&#xE9; E, Campo E, Sancho-Cia JM and L&#xF3;pez-Guillermo A. Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. Br J Haematol 2019; 184: 753-759.","journal-title":"Br J Haematol"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","unstructured":"Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, L&#xF3;pez-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, Andr&#xE9; M, Zach&#xE9;e P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L and Salles GA; RELEVANCE Trial Investigators. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 2018; 379: 934-947.","journal-title":"N Engl J Med"},{"key":"ref126","doi-asserted-by":"publisher","unstructured":"Federico M, Caballero Barrig&#xF3;n MD, Marcheselli L, Tarantino V, Manni M, Sarkozy C, Alonso-&#xC1;lvarez S, Wondergem M, Cartron G, Lopez-Guillermo A, Issa D, Morschhauser F, Alcoceba M, Kimby E, Rusconi C, Chamuleau M, Holte H, Lockmer S, Montoto S, Gomes da Silva M, Aurer I, Zucca E, Paszkiewicz-Kozik E, Minoia C, Skrypets T, Blaker YN, Salles G and Coiffier B; Aristotle Consortium. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol 2018; 5: e359-e367.","DOI":"10.1016\/S2352-3026(18)30090-5"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","article-title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial","volume":"131","author":"Bartlett","year":"2018","unstructured":"Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, Thye LS, Anderson DM, Krysiak K, Ramirez C, Qi J, Siegel BA, Griffith M, Griffith OL, Gomez F and Fehniger TA. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood 2018; 131: 182-190.","journal-title":"Blood"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bjh.16424","article-title":"The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma","volume":"189","author":"Fowler","year":"2020","unstructured":"Fowler NH, Nastoupil L, De Vos S, Knapp M, Flinn IW, Chen R, Advani RH, Bhatia S, Martin P, Mena R, Davis RE, Neelapu SS, Eckert K, Ping J, Co M, Beaupre DM, Neuenburg JK and Palomba ML. The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma. Br J Haematol 2020; 189: 650-660.","journal-title":"Br J Haematol"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1182\/blood-2022-159158","article-title":"Acalabrutinib plus rituximab with or without lenalidomide in patients with follicular lymphoma: a multipart, open-label, phase 1b trial","volume":"140","author":"Strati","year":"2022","unstructured":"Strati P, Christian B, Martin P, Champion B, Coleman M, Agajanian R, Smith SM, Venugopal P, Lossos IS and Kridel R. Acalabrutinib plus rituximab with or without lenalidomide in patients with follicular lymphoma: a multipart, open-label, phase 1b trial. Blood 2022; 140: 3606-3608.","journal-title":"Blood"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/bjh.14857","article-title":"Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors","volume":"182","author":"Jain","year":"2018","unstructured":"Jain P, Kanagal-Shamanna R, San Lucas FA, Nastoupil L, Romaguera J, Fayad L, Oki Y, Westin JR, Medeiros LJ, Wang M and Fowler N. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. Br J Haematol 2018; 182: 718-723.","journal-title":"Br J Haematol"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1159\/000532090","article-title":"Efficacy of autologous hematopoietic stem cell transplantation versus chemotherapy or allogeneic hematopoietic stem cell transplantation for follicular lymphoma: systematic review and meta-analysis","volume":"101","author":"Liu","year":"2023","unstructured":"Liu X, Zheng Y, Li H, Wang M, You MJ and Tian C. Efficacy of autologous hematopoietic stem cell transplantation versus chemotherapy or allogeneic hematopoietic stem cell transplantation for follicular lymphoma: systematic review and meta-analysis. Oncology 2023; 101: 822-835.","journal-title":"Oncology"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German low grade lymphoma study group","volume":"24","author":"Jurinovic","year":"2018","unstructured":"Jurinovic V, Metzner B, Pfreundschuh M, Schmitz N, Wandt H, Keller U, Dreger P, Dreyling M, Hiddemann W, Unterhalt M, Hoster E and Weigert O. Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German low grade lymphoma study group. Biol Blood Marrow Transplant 2018; 24: 1172-1179.","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jtct.2024.06.025","article-title":"Clinical practice recommendations for hematopoietic cell transplantation and cellular therapies in follicular lymphoma: a collaborative effort on behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation","volume":"30","author":"Iqbal","year":"2024","unstructured":"Iqbal M, Kumar A, Dreger P, Chavez J, Sauter CS, Sureda AM, Bachanova V, Maziarz RT, Dreyling M, Smith SM, Jacobson C, Glass B, Casulo C, Oluwole OO, Montoto S, Advani R, Cohen J, Salles G, Hamad N, Kuruvilla J, Kahl BS, Shadman M, Kanate AS, Budde LE, Kamdar M, Flowers C, Hamadani M and Kharfan-Dabaja MA. Clinical practice recommendations for hematopoietic cell transplantation and cellular therapies in follicular lymphoma: a collaborative effort on behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation. Transplant Cell Ther 2024; 30: 832-843.","journal-title":"Transplant Cell Ther"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/ejh.13691","article-title":"Long-term outcome in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation","volume":"107","author":"Metzner","year":"2021","unstructured":"Metzner B, Pott C, M&#xFC;ller TH, Casper J, Kimmich C, Petershofen EK, Renzelmann A, Rosien B, Thole R, Vo&#xDF; A, K&#xF6;hne CH and Wellnitz D. Long-term outcome in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation. Eur J Haematol 2021; 107: 543-552.","journal-title":"Eur J Haematol"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1182\/blood.2019001843","article-title":"The case for CAR T-cell therapy in follicular lymphomas","volume":"134","author":"Bishop","year":"2019","unstructured":"Bishop MR. The case for CAR T-cell therapy in follicular lymphomas. Blood 2019; 134: 577-578.","journal-title":"Blood"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","volume":"134","author":"Hirayama","year":"2019","unstructured":"Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Riddell SR, Maloney DG and Turtle CJ. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood 2019; 134: 636-640.","journal-title":"Blood"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.beha.2018.04.001","article-title":"CAR T cell therapy for B-cell lymphomas","volume":"31","author":"Chavez","year":"2018","unstructured":"Chavez JC and Locke FL. CAR T cell therapy for B-cell lymphomas. Best Pract Res Clin Haematol 2018; 31: 135-146.","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"100826","DOI":"10.1016\/j.currproblcancer.2021.100826","article-title":"CAR T-cell therapy for B-cell lymphoma","volume":"46","author":"Denlinger","year":"2022","unstructured":"Denlinger N, Bond D and Jaglowski S. CAR T-cell therapy for B-cell lymphoma. Curr Probl Cancer 2022; 46: 100826.","journal-title":"Curr Probl Cancer"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00277-017-3154-z","article-title":"Current prognostic and predictive factors in follicular lymphoma","volume":"97","author":"Sorigue","year":"2018","unstructured":"Sorigue M and Sancho JM. Current prognostic and predictive factors in follicular lymphoma. Ann Hematol 2018; 97: 209-227.","journal-title":"Ann Hematol"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","unstructured":"Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Soumerai JD, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Kumar A, Matasar MJ, Moskowitz AJ, Moskowitz CH, Noy A, Owens C, Palomba LM, Straus D, von Keudell G, Zelenetz AD, Seshan VE and Younes A. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J 2020; 10: 74.","journal-title":"Blood Cancer J"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bjh.16872","article-title":"The investigation and management of follicular lymphoma","volume":"191","author":"McNamara","year":"2020","unstructured":"McNamara C, Montoto S, Eyre TA, Ardeshna K, Burton C, Illidge T, Linton K, Rule S, Townsend W, Wong WL and McKay P. The investigation and management of follicular lymphoma. Br J Haematol 2020; 191: 363-381.","journal-title":"Br J Haematol"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/cancers12061565","article-title":"Management of drug resistance in mantle cell lymphoma","volume":"12","author":"Rou&#xE9","year":"2020","unstructured":"Rou&#xE9; G and Sola B. Management of drug resistance in mantle cell lymphoma. Cancers (Basel) 2020; 12: 1565.","journal-title":"Cancers (Basel)"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"100822","DOI":"10.1016\/j.drup.2022.100822","article-title":"Targeting metabolism to overcome cancer drug resistance: a promising therapeutic strategy for diffuse large B cell lymphoma","volume":"61","author":"Pi","year":"2022","unstructured":"Pi M, Kuang H, Yue C, Yang Q, Wu A, Li Y, Assaraf YG, Yang DH and Wu S. Targeting metabolism to overcome cancer drug resistance: a promising therapeutic strategy for diffuse large B cell lymphoma. Drug Resist Updat 2022; 61: 100822.","journal-title":"Drug Resist Updat"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.3390\/ijms21062081","article-title":"Drug resistance in non-Hodgkin lymphomas","volume":"21","author":"Klener","year":"2020","unstructured":"Klener P and Klanova M. Drug resistance in non-Hodgkin lymphomas. Int J Mol Sci 2020; 21: 2081.","journal-title":"Int J Mol Sci"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/cam4.1918","article-title":"The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: a combined analysis of 3 CALGB trials","volume":"8","author":"Lansigan","year":"2019","unstructured":"Lansigan F, Barak I, Pitcher B, Jung SH, Cheson BD, Czuczman M, Martin P, Hsi E, Sch&#xF6;der H, Smith S, Bartlett NL, Leonard JP and Blum KA. The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: a combined analysis of 3 CALGB trials. Cancer Med 2019; 8: 165-173.","journal-title":"Cancer Med"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3324\/haematol.2017.184192","article-title":"Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy","volume":"103","author":"de Charette","year":"2018","unstructured":"de Charette M and Houot R. Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy. Haematologica 2018; 103: 1256-1268.","journal-title":"Haematologica"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/CM9.0000000000001294","article-title":"R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms","volume":"134","author":"Wang","year":"2020","unstructured":"Wang L and Li LR. R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms. Chin Med J (Engl) 2020; 134: 253-260.","journal-title":"Chin Med J (Engl)"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.3390\/cancers13174363","article-title":"Apoptosis deregulation and the development of cancer multi-drug resistance","volume":"13","author":"Neophytou","year":"2021","unstructured":"Neophytou CM, Trougakos IP, Erin N and Papageorgis P. Apoptosis deregulation and the development of cancer multi-drug resistance. Cancers (Basel) 2021; 13: 4363.","journal-title":"Cancers (Basel)"},{"key":"ref149","doi-asserted-by":"publisher","unstructured":"Bargetzi M, Baumann R, Cogliatti S, Dietrich PY, Duchosal M, Goede J, Hitz F, Konermann C, Lohri A, Mey U, Novak U, Papachristofilou A, Stenner F, Taverna C, Zander T and Renner C. Diagnosis and treatment of follicular lymphoma: an update. Swiss Med Wkly 2018; 148: w14635.","DOI":"10.4414\/smw.2018.14635"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1053\/j.semnuclmed.2017.09.004","article-title":"PET\/CT for lymphoma post-therapy response assessment in other lymphomas, response assessment for autologous stem cell transplant, and lymphoma follow-up","volume":"48","author":"Karls","year":"2018","unstructured":"Karls S, Shah H and Jacene H. PET\/CT for lymphoma post-therapy response assessment in other lymphomas, response assessment for autologous stem cell transplant, and lymphoma follow-up. Semin Nucl Med 2018; 48: 37-49.","journal-title":"Semin Nucl Med"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/hon.2540","article-title":"Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper","volume":"37","author":"Cuneo","year":"2019","unstructured":"Cuneo A, Barosi G, Danesi R, Fagiuoli S, Ghia P, Marzano A, Montillo M, Poletti V, Viale P and Zinzani PL. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper. Hematol Oncol 2019; 37: 3-14.","journal-title":"Hematol Oncol"},{"key":"ref152","doi-asserted-by":"publisher","unstructured":"Y&#xE1;&#xF1;ez L, S&#xE1;nchez-Escamilla M and Perales MA. CAR T cell toxicity: current management and future directions. Hemasphere 2019; 3: e186.","DOI":"10.1097\/HS9.0000000000000186"},{"key":"ref153","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3324\/haematol.2021.278717","article-title":"Prospects in the management of patients with follicular lymphoma beyond first-line therapy","volume":"107","author":"Qualls","year":"2022","unstructured":"Qualls D and Salles G. Prospects in the management of patients with follicular lymphoma beyond first-line therapy. Haematologica 2022; 107: 19-34.","journal-title":"Haematologica"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.clml.2020.03.009","article-title":"Management of adverse events from the combination of rituximab and lenalidomide in the treatment of patients with follicular and low-grade non-Hodgkin lymphoma","volume":"20","author":"BD","year":"2020","unstructured":"Cheson BD, Morschhauser F and Martin P. Management of adverse events from the combination of rituximab and lenalidomide in the treatment of patients with follicular and low-grade non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2020; 20: 563-571.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/blood.2019000847","article-title":"The immune landscape and response to immune checkpoint blockade therapy in lymphoma","volume":"135","author":"Kline","year":"2020","unstructured":"Kline J, Godfrey J and Ansell SM. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood 2020; 135: 523-533.","journal-title":"Blood"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"5456","DOI":"10.3390\/ijms21155456","article-title":"Immune-checkpoint blockade therapy in lymphoma","volume":"21","author":"Kuzume","year":"2020","unstructured":"Kuzume A, Chi S, Yamauchi N and Minami Y. Immune-checkpoint blockade therapy in lymphoma. Int J Mol Sci 2020; 21: 5456.","journal-title":"Int J Mol Sci"},{"key":"ref157","doi-asserted-by":"publisher","unstructured":"Davoodi-Moghaddam Z, Jafari-Raddani F, Noori M and Bashash D. A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe? Transl Oncol 2023; 30: 101636.","DOI":"10.1016\/j.tranon.2023.101636"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/12\/ajcr0158957.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:51:18Z","timestamp":1766022678000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/12\/ajcr0158957.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":158,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/mfug2190","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}